Found 7 hits in this display Target/Host
(Institution) | Ligand | Target/Host
Links | Ligand
Links | Trg + Lig
Links | Ki
nM | ΔG°
kJ/mole | IC50
nM | Kd
nM | EC50/IC50
nM | koff
s-1 | kon
M-1s-1 | pH | Temp
°C |
|---|
Caspase-1
(Homo sapiens (Human)) | BDBM160783
(US10167313, Compound 50 | US9045524, 50)Show SMILES CC(C)[C@H](NC(=O)[C@H](Cc1ccc2ccccc2n1)NS(=O)(=O)c1ccc(C)cc1)C(=O)N[C@@H](CC(O)=O)\C=C(/Cl)S(C)(=O)=O |r| Show InChI InChI=1S/C30H35ClN4O8S2/c1-18(2)28(30(39)33-22(17-27(36)37)16-26(31)44(4,40)41)34-29(38)25(35-45(42,43)23-13-9-19(3)10-14-23)15-21-12-11-20-7-5-6-8-24(20)32-21/h5-14,16,18,22,25,28,35H,15,17H2,1-4H3,(H,33,39)(H,34,38)(H,36,37)/b26-16+/t22-,25+,28+/m1/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | >3.33E+3 | n/a | n/a | n/a | n/a | n/a | 37 |
NOVAGENESIS FOUNDATION
US Patent
| Assay Description
Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas... |
US Patent US9045524 (2015)
BindingDB Entry DOI: 10.7270/Q2GT5KX8 |
More data for this
Ligand-Target Pair | |
Caspase-5
(Homo sapiens (Human)) | BDBM160783
(US10167313, Compound 50 | US9045524, 50)Show SMILES CC(C)[C@H](NC(=O)[C@H](Cc1ccc2ccccc2n1)NS(=O)(=O)c1ccc(C)cc1)C(=O)N[C@@H](CC(O)=O)\C=C(/Cl)S(C)(=O)=O |r| Show InChI InChI=1S/C30H35ClN4O8S2/c1-18(2)28(30(39)33-22(17-27(36)37)16-26(31)44(4,40)41)34-29(38)25(35-45(42,43)23-13-9-19(3)10-14-23)15-21-12-11-20-7-5-6-8-24(20)32-21/h5-14,16,18,22,25,28,35H,15,17H2,1-4H3,(H,33,39)(H,34,38)(H,36,37)/b26-16+/t22-,25+,28+/m1/s1 | KEGG
UniProtKB/SwissProt
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | >3.33E+3 | n/a | n/a | n/a | n/a | n/a | 37 |
NOVAGENESIS FOUNDATION
US Patent
| Assay Description
Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas... |
US Patent US9045524 (2015)
BindingDB Entry DOI: 10.7270/Q2GT5KX8 |
More data for this
Ligand-Target Pair | |
Caspase-7
(Homo sapiens (Human)) | BDBM160783
(US10167313, Compound 50 | US9045524, 50)Show SMILES CC(C)[C@H](NC(=O)[C@H](Cc1ccc2ccccc2n1)NS(=O)(=O)c1ccc(C)cc1)C(=O)N[C@@H](CC(O)=O)\C=C(/Cl)S(C)(=O)=O |r| Show InChI InChI=1S/C30H35ClN4O8S2/c1-18(2)28(30(39)33-22(17-27(36)37)16-26(31)44(4,40)41)34-29(38)25(35-45(42,43)23-13-9-19(3)10-14-23)15-21-12-11-20-7-5-6-8-24(20)32-21/h5-14,16,18,22,25,28,35H,15,17H2,1-4H3,(H,33,39)(H,34,38)(H,36,37)/b26-16+/t22-,25+,28+/m1/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | >3.33E+3 | n/a | n/a | n/a | n/a | n/a | 37 |
NOVAGENESIS FOUNDATION
US Patent
| Assay Description
Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas... |
US Patent US9045524 (2015)
BindingDB Entry DOI: 10.7270/Q2GT5KX8 |
More data for this
Ligand-Target Pair | |
Caspase-3
(Homo sapiens (Human)) | BDBM160783
(US10167313, Compound 50 | US9045524, 50)Show SMILES CC(C)[C@H](NC(=O)[C@H](Cc1ccc2ccccc2n1)NS(=O)(=O)c1ccc(C)cc1)C(=O)N[C@@H](CC(O)=O)\C=C(/Cl)S(C)(=O)=O |r| Show InChI InChI=1S/C30H35ClN4O8S2/c1-18(2)28(30(39)33-22(17-27(36)37)16-26(31)44(4,40)41)34-29(38)25(35-45(42,43)23-13-9-19(3)10-14-23)15-21-12-11-20-7-5-6-8-24(20)32-21/h5-14,16,18,22,25,28,35H,15,17H2,1-4H3,(H,33,39)(H,34,38)(H,36,37)/b26-16+/t22-,25+,28+/m1/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | >3.33E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Genesis Technologies Limited
US Patent
| Assay Description
Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas... |
US Patent US10167313 (2019)
BindingDB Entry DOI: 10.7270/Q2Q81G59 |
More data for this
Ligand-Target Pair | |
Caspase-3
(Homo sapiens (Human)) | BDBM160783
(US10167313, Compound 50 | US9045524, 50)Show SMILES CC(C)[C@H](NC(=O)[C@H](Cc1ccc2ccccc2n1)NS(=O)(=O)c1ccc(C)cc1)C(=O)N[C@@H](CC(O)=O)\C=C(/Cl)S(C)(=O)=O |r| Show InChI InChI=1S/C30H35ClN4O8S2/c1-18(2)28(30(39)33-22(17-27(36)37)16-26(31)44(4,40)41)34-29(38)25(35-45(42,43)23-13-9-19(3)10-14-23)15-21-12-11-20-7-5-6-8-24(20)32-21/h5-14,16,18,22,25,28,35H,15,17H2,1-4H3,(H,33,39)(H,34,38)(H,36,37)/b26-16+/t22-,25+,28+/m1/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | >3.33E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
NOVAGENESIS FOUNDATION
US Patent
| Assay Description
To test the efficacy of caspase-3 inhibitors at the cellular level, the ability of selected compounds to inhibit the proteolytic cleavage of PARP (po... |
US Patent US9045524 (2015)
BindingDB Entry DOI: 10.7270/Q2GT5KX8 |
More data for this
Ligand-Target Pair | |
Caspase-1
(Homo sapiens (Human)) | BDBM160783
(US10167313, Compound 50 | US9045524, 50)Show SMILES CC(C)[C@H](NC(=O)[C@H](Cc1ccc2ccccc2n1)NS(=O)(=O)c1ccc(C)cc1)C(=O)N[C@@H](CC(O)=O)\C=C(/Cl)S(C)(=O)=O |r| Show InChI InChI=1S/C30H35ClN4O8S2/c1-18(2)28(30(39)33-22(17-27(36)37)16-26(31)44(4,40)41)34-29(38)25(35-45(42,43)23-13-9-19(3)10-14-23)15-21-12-11-20-7-5-6-8-24(20)32-21/h5-14,16,18,22,25,28,35H,15,17H2,1-4H3,(H,33,39)(H,34,38)(H,36,37)/b26-16+/t22-,25+,28+/m1/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | >3.33E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Genesis Technologies Limited
US Patent
| Assay Description
Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas... |
US Patent US10167313 (2019)
BindingDB Entry DOI: 10.7270/Q2Q81G59 |
More data for this
Ligand-Target Pair | |
Caspase-9
(Homo sapiens (Human)) | BDBM160783
(US10167313, Compound 50 | US9045524, 50)Show SMILES CC(C)[C@H](NC(=O)[C@H](Cc1ccc2ccccc2n1)NS(=O)(=O)c1ccc(C)cc1)C(=O)N[C@@H](CC(O)=O)\C=C(/Cl)S(C)(=O)=O |r| Show InChI InChI=1S/C30H35ClN4O8S2/c1-18(2)28(30(39)33-22(17-27(36)37)16-26(31)44(4,40)41)34-29(38)25(35-45(42,43)23-13-9-19(3)10-14-23)15-21-12-11-20-7-5-6-8-24(20)32-21/h5-14,16,18,22,25,28,35H,15,17H2,1-4H3,(H,33,39)(H,34,38)(H,36,37)/b26-16+/t22-,25+,28+/m1/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | >3.33E+3 | n/a | n/a | n/a | n/a | n/a | 37 |
NOVAGENESIS FOUNDATION
US Patent
| Assay Description
Selectivity of compound 55, compound 63, compound 48, compound 57, compound 88 toward caspase-1 (pro-inflammatory group), caspase-5 (group I), caspas... |
US Patent US9045524 (2015)
BindingDB Entry DOI: 10.7270/Q2GT5KX8 |
More data for this
Ligand-Target Pair | |